Biocon Biologics

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA)

Yesintek is a biosimilar to Stelara (ustekinumab) and is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque…

European Medicines Agency’s CHMP recommends approval of Biocon Biologics' denosumab biosimilars for bone health indications

Settlement agreement allows Biocon Biologics to commercialise interchangeable aflibercept biosimilar Yesafili in the US; launch…

The approval marks Biocon Biologics’ seventh biosimilar clearance in the US, expanding its oncology portfolio in one of the…

The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study

Biocon Biologics enters US market with YESINTEK, offering treatment options for Crohn’s disease, ulcerative colitis, plaque…

Biocon’s subsidiary Biocon Biologics, which also participated independently in the assessment for the first time, reported an…

The VAI classification was given to Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia

The company transformed from a two-country operation focused on Development and Manufacturing, to a fully integrated company